Compare Garmin Ltd. (GRMN) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Sana Biotechnology Inc — how do they compare? Garmin Ltd. trades at $309.51 (market cap $59.72B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Garmin Ltd. is far larger — about 52.8× Sana Biotechnology Inc's market cap, and Garmin Ltd. pays a 1.36% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| GRMN | SANA | |
|---|---|---|
Market Cap | $59.72B | $1.13B |
Sector | Technology | Health |
52-Week High | $313.16 | $5.92 |
52-Week Low | $187.10 | $2.68 |
Enterprise Value | $57.23B | $1.05B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $310.07, near its all-time high, with a slight daily decline of 0.99%. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate potential overbought conditions. Fundamentally, the company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.81 surpassing estimates of $2.30, and raised full-year guidance. Revenue growth remains robust, supported by strength in the fitness segment, while profitability metrics like a 60.08% gross margin highlight operational efficiency.
The outlook for GRMN is positive, driven by sustained demand in wearables and fitness technology, but risks include rich valuation multiples and potential growth deceleration. Analyst consensus is a 'Hold' with a $318.67 price target, suggesting limited near-term upside. Investors should weigh strong execution against premium pricing and competitive pressures in the consumer hardware space.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
